Agios Pharmaceuticals | AGIO - Cash And Equivalent

Stock Price
28.17
Daily Change
-0.56 -1.95%
Monthly
-19.33%
Yearly
-3.46%
Q2 Forecast
27.60

Agios Pharmaceuticals reported $113.6M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Astellas Pharma JPY 188.37B 8.51B Mar/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Exelixis USD 226.15M 256.34M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.91B 687M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.7B 561M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026